RxDoctor Payments Data

Andrew Pace, MD

Dermatology · Tacoma, WANPI 1881929560

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $806 of the $1,004 with a category attached, or 80.3%. 9 manufacturers reported payments, led by AbbVie at 33.4% of the total.

$1,004in general payments, 2019–2025

Across 47 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$336
  • Johnson & Johnson$233
  • Sun Pharmaceutical Industries Inc.$138
  • Novartis$82
  • Dermavant Sciences, Inc.$77
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$42
  • plus $96 from 3 others
$194,263in research payments, 2019–2025

Across 48 payments — averaging $4047.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$99K
  • Pfizer$84K
  • Novartis$11K

What the payments were for

  • Food & beverage$80680%
  • Education$19820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,004 in reported general payments places this provider in the 55th percentile of 323 dermatology providers in Washington.

See all dermatology providers in Washington

Medicare billing

Part B allowed, 2024
$500,927
Medicare patients
755
Services billed
5,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$56,858
Clobetasol Propionate109$3,892
Ketoconazole173$3,516
Metronidazole73$2,803
Fluorouracil26$1,704
Clindamycin Phosphate30$1,350
Doxycycline Monohydrate33$1,276
Doxycycline Hyclate13$1,021
Ciclopirox44$783
Triamcinolone Acetonide109$779
Hydroxychloroquine Sulfate27$461
Hydrocortisone67$399
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc13$323
Acyclovir32$114
Prednisone14$112

Paid to pharmacies, not to this prescriber.

Other dermatology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →